A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder (Q33994634)

30 July 2017

1 reference

title

A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder (English)

1 reference

obsessive-compulsive disorder

30 July 2017

main subject

0 references

1 reference

M H Bloch

1

1 reference

30 July 2017

A Landeros-Weisenberger

2

1 reference

30 July 2017

B Kelmendi

3

1 reference

30 July 2017

V Coric

4

1 reference

30 July 2017

M B Bracken

5

1 reference

30 July 2017

J F Leckman

6

1 reference

30 July 2017

language of work or name

English

0 references

publication date

4 April 2006

1 reference

30 July 2017

1 reference

30 July 2017

volume

11

1 reference

30 July 2017

issue

7

1 reference

30 July 2017

page(s)

622-632

1 reference

Uncomplicated and comorbid obsessive-compulsive disorder in an epidemiologic sample

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

Quality of life for patients with obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

The epidemiology of obsessive-compulsive disorder in five US communities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

Follow-up studies in obsessional neurosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

OBSESSIONAL NEUROTICS: A LONG-TERM FOLLOW-UP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

Pharmacological management of obsessive-compulsive disorder: a review for clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

Clinical predictors of drug response in obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

A placebo-controlled trial of risperidone in Tourette syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

Obsessive-compulsive Disorder and Primary Unipolar Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

7 January 2021

Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

7 January 2021

A 40-year follow-up of patients with obsessive-compulsive disorder [see commetns]

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

7 January 2021

[Long-term catamnesis of obsessive-compulsive neuroses]

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

7 January 2021

On the problem of compulsive disease with special reference to its hereditary relations

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

7 January 2021

Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

7 January 2021

Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

7 January 2021

A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

7 January 2021

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

7 January 2021

A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

7 January 2021

Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001823

7 January 2021

Identifiers

DOI

10.1038/SJ.MP.4001823

1 reference

30 July 2017

1 reference